Navigation Links
ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR

LOS ANGELES--(BUSINESS WIRE)--Apr 17, 2007 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today the presentation of preclinical data strongly supportive of the development of an oral form of ZIO-101. Specifically, ZIO-101 demonstrates very high bioavailability when administered orally; in addition it evidences anti-angiogenic activity that is particularly well suited to oral administration. These data were presented in two separate posters today at the American Association of Cancer Research (AACR) meeting being held in Los Angeles.

Philip Komarnitsky, M.D., Ph.D., of ZIOPHARM, and colleagues presented data showing that the administration of ZIO-101 results in dramatically reduced new blood vessel formation in a mouse model of angiogenesis. Anti-angiogenic therapy that utilizes lower doses of the administered drug given over sustained periods of time is particularly well suited to drugs that can be orally administered. Data from pharmacokinetic analysis of orally administered ZIO-101 in animals showed very high bioavailability.

Lawrence Boise, Ph.D., from the University of Miami, and colleagues also presented additional data supporting a ZIO-101 mechanism of action that is distinct from that of arsenic trioxide, an inorganic arsenic that is currently approved for the treatment of a rare form of leukemia and used in the treatment of advanced multiple myeloma. Differences in the way the two drugs activate genes and in their mechanisms of action suggest that ZIO-101 is likely to be active against cancer cells that are resistant to arsenic trioxide.

"These preclinical data are strongly supportive of the Company's development strategy for both oral and IV ZIO-101," commented Jonathan Lewis, M.D., Ph.D., Chief Executive Officer. "ZIO-101 is currently in three separate phase II trials in blood and solid cancers and we expect to initiate clinical study with an oral form in the second half of 2007."

About ZIO-101

ZIO-101 is a proprietary small molecule organic arsenic licensed from The University of Texas M. D. Anderson Cancer Center and Texas A&M University. ZIO-101 induces cell cycle arrest and cell death by targeting several cellular pathways essential for cell survival. Exposure to ZIO-101 has a direct as well as indirect effect on mitochondrial functions, resulting in depletion of energy supply to the cell and induction of apoptosis (programmed cell death). Increase in intra-cellular Reactive Oxygen Species enhances this effect on mitochondrial functions and consequently the activation of the signal transduction pathway leading to apoptosis. In addition, ZIO-101 interrupts the cell cycle at the G2/M phase of tumor cells inducing cell death through this pathway as well.

About ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. For more information, visit www.ziopharm.com.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its prod uct candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, and risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates. The Company assumes no obligation to update these forward-looking statements, except as required by law.

ZIOP-G

Contact

ZIOPHARM Oncology, Inc.
Investors
Suzanne McKenna, 646-214-0703
smckenna@ziopharm.com
or
Media
Tina Posterli, 917-322-2565
tposterli@rxir.com


'"/>




Related medicine technology :

1. ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR
3. ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR
4. ZIOPHARM Presents ZIO-201 Lymphoma Data at ISH
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
8. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
9. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 22, 2017 FinancialBuzz.com News Commentary ... rapidly due to the significant development and innovation in ... Market Research, the global electrophysiology market was worth $3.42 ... billion by 2022, with a GAGR of 13.4%. Electrophysiology ... diagnose abnormal heartbeats or arrhythmia. The report indicates that ...
(Date:3/22/2017)... GROVE, Minn. , March 22, 2017   Upsher-Smith ... Clomipramine Hydrochloride Capsules* USP, 25 mg, 50 mg and 75 ... (clomipramine hydrochloride) Capsules USP. The clomipramine hydrochloride ... the 12 months ending December 2016, according to IMS Health. ... "Upsher-Smith ...
(Date:3/22/2017)... 22, 2017  As the world,s leading non-profit dedicated ... (LLS) has played a role in most therapies used ... are even helping patients with other cancers and serious ... investment in cutting-edge research – more than $1 billion ... with the record-breaking sum of $4.1 million raised at ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 23, 2017 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it had won the ‘Clinical ... at the Suntec Singapore International Exhibition & Convention Centre, Singapore. The award was ...
(Date:3/22/2017)... ... 2017 , ... Old School Labs™, makers of the best-selling Vintage line of ... Ambassador. Theophane, who trained with Floyd Mayweather, made his professional debut in London in ... an impressive number of wins in contests in Britain, Germany and the U.S. ...
(Date:3/22/2017)... ... 22, 2017 , ... Wash Tower Ltd. has released a series of six ... the world's first standalone constant pressure bidet. , The videos in the series titled ... https://www.washtower.com as well as on its social media pages. , Each video stars ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... Drs. Jennifer ... their patient base to accept new patients in need of skilled pediatric dentistry ... India Hook Dental Care offers pediatric patients routine treatments, including cavities, sealants and fluoride ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... lab with extensive therapeutic experience and operational excellence in oncology clinical trials, proudly ... trial for the treatment of non-small cell lung cancer and small cell lung ...
Breaking Medicine News(10 mins):